MedTrace Logo

Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

NCT01414244 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2017-08-09

Study results available
· View outcomes & findings →

Summary

New and effective treatments are needed for patients with post-infectious irritable bowel syndrome (PI-IBS). We conducted a randomized, placebo-controlled trial to assess the efficacy and safety of glutamine, an abundant amino acid in the body and the principal fuel for enterocytes, in patients who developed diarrhea-predominant irritable bowel syndrome with increased intestinal permeability following an enteric infection.

Conditions

  • Diarrhea-Predominant Irritable Bowel Syndrome

Interventions

DRUG

Glutamine

Drug

Sponsors & Collaborators

  • Tulane University

    lead OTHER

Principal Investigators

  • QiQi Zhou · Tulane University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2015-12-30
Completion
2015-12-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01414244 on ClinicalTrials.gov